絞り込み

16532

広告

Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.

著者 Schafer JH , Casey AL , Dupre KA , Staubes BA
Ann Pharmacother.2018 Jun 01 ; ():1060028018781853.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (22view , 0users)

Full Text Sources

Because of a lack of comparative data on anticoagulant use in the advanced chronic kidney disease (CKD) population, guidelines recommend warfarin for atrial fibrillation and venous thromboembolism (VTE) treatment in these patients. However, apixaban has specific dosing recommendations in CKD leading to use in clinical practice.
PMID: 29871510 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード